SCHEMBL6322749

SCHEMBL6322749

CC(NC(=O)c1c(-c2ccc(Br)s2)noc1N)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
HDAC3 O15379 3/20 0.47
HDAC4 P56524 3/20 0.47
HDAC1 Q13547 3/20 0.47
ALDH1A1 P00352 6/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HDAC6 Q9UBN7 3/20 0.44
LMNA P02545 2/20 0.43
TSHR P16473 1/20 0.43
KDM4E B2RXH2 1/20 0.43
THRB P10828 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320735 0.89 L3MBTL1 (0.52) L3MBTL1HDAC3HDAC4HDAC1ALDH1A1
SCHEMBL6317518 0.87 CA1 (0.54) L3MBTL1HDAC3HDAC4HDAC1ALDH1A1
SCHEMBL6317709 0.87 CA1 (0.44) L3MBTL1ALDH1A1MEN1KMT2ALMNA
SCHEMBL6318494 0.86 L3MBTL1 (0.47) L3MBTL1HDAC3HDAC4HDAC1ALDH1A1
SCHEMBL6315062 0.84 CA1 (0.43) L3MBTL1ALDH1A1MEN1KMT2ALMNA
SCHEMBL6321608 0.84 ALDH1A1 (0.40) ALDH1A1
SCHEMBL6316025 0.83 POLB (0.48) ALDH1A1MEN1KMT2ALMNATSHR
SCHEMBL6616829 0.83 RXFP1 (0.45) HDAC3HDAC4HDAC1ALDH1A1KMT2A
SCHEMBL6317895 0.83 CA1 (0.41) L3MBTL1ALDH1A1MEN1KMT2ATSHR
SCHEMBL6317595 0.82 CA1 (0.41) L3MBTL1ALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 L3MBTL1 4176/4885HDAC3 1462/4885HDAC4 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.